Assessing the efficacy of drugs for the acute treatment of migraine: Issues in clinical trial design

CNS Drugs

Volumn 16, Issue 3, 2002, Pages 181-196

  Ramadan, Nabih M ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; PLACEBO;

ANALGESIA; AREA UNDER THE CURVE; CLINICAL TRIAL; DISABILITY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; METHODOLOGY; MIGRAINE; PAIN; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SAMPLE SIZE; STATISTICAL ANALYSIS;

EID: 0036220352     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216030-00005     Document Type: Review

References (45)

1. Guidelines for controlled trials of drugs in migraine
2. Guidelines for controlled trials of drugs in migraine
3. The international conference on harmonization good clinical practice guideline
4. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain
5. Learning versus confirming in clinical drug development
6. Comparison of the efficacy of zolmitriptan and sumatriptan: Issues in migraine trial design
7. Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan
8. Experimental pain models
9. Placebo effect in the acute treatment of migraine: Subcutaneous placebos are better than oral placebos
10. Ethical principles for medical research involving human subjects
11. Design and analysis of cross-over trials
12. Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies?
13. Effect of migraine attacks on paracetamol absorption
14. Efficacy definitions for migraine studies
15. Determinants of patient satisfaction with migraine therapy
16. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy
17. Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraine
18. Optimizing the dose of zolmitriptan (Zomig,* 311 C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled dose range-finding study
19. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study
20. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study
21. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks
22. Symptomatology of migraine without aura
23. Migraine
24. How to assess and compare drugs in the management of migraine: Success rate in terms of response and recurrence
25. Crossover comparison of rizatriptan 5 mg and 10 mg and sumatriptan 25 mg and 50 mg
26. Assessing the onset of relief of a treatment for migraine
27. Oral rizatriptan vs. oral sumatriptan: A direct comparative study in the acute treatment of migraine
28. A multinational investigation of the impact of subcutaneous sumatriptan: IV. Patient satisfaction
29. Migraine symptoms: Results of a survey of self-reported migraineurs
30. Time-to-event analysis, or who gets better sooner? An emerging concept in headache study methodology
31. Ineffectiveness of neurokinin-1 antagonist in acute migraine
32. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale
33. Meta-analysis of the efficacy of rizatriptan for treating migraine symptoms
34. Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types
35. Zolmitriptan provides consistent migraine relief when used in the long-term
36. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine: An international study
37. Oral sumatriptan for the long-term treatment of migraine: Clinical findings
38. Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months)
39. Within-patient consistency of response of rizatriptan for treating migraine
40. Long-term efficacy of subcutaneous sumatriptan using a novel self-injector
41. Methodological issues in acute migraine clinical trials
42. Burden of migraine in the United States: Disability and economic costs
43. How to assess patient preference of migraine treatments
44. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan